Somnomed Limited · ASX:SOM
Somnomed — H1 FY2015 Earnings Presentation
12 slides from Somnomed's earnings presentation, Feb 18, 2015
Slide 1: Investor Presentation Financial Year 2014-15 Half Year Review
For personal use only Investor Presentation Financial Year 2014 – 15 Half Year Review 18 February, 2015 COAT ™ Continuous Open Airway Therapy
Slide 2: Disclaimer & Regulatory Disclosure
For personal use only Disclaimer & Regulatory Disclosure This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: SomnoMed Summary – First Half FY2015
SomnoMed: Global SomnoMed Summary – First Half FY2015 For personal use only 1 2 3 SomnoDent® Units sold totaled 24,775 Revenues reached $14.8 million MAS Gross Margin improved to 68.5% (+21.1%) (+18%) Units Sold Revenues ($000's) 30000 30,000 16000 16,000 25,000 25000 14000 14,000 12000 12,000 20,00
Slide 4: Global highlights of the first half financial year 2014/15
SomnoMed: Global Global highlights of the first half financial year 2014/15 For personal use only • Strong growth in volume and revenues: o Total volume of devices sold of 24,775 and growth of 21.1% year on year as per guidance o Total revenues $14.8 million and growth of 18% year on year - above gu
Slide 5: Unit Sales Volume Accelerates
SomnoMed: Global Unit Sales Volume Accelerates For personal use only 15,000 14,000 13,000 12,000 11,000 10,000 9,000 8,000 7,000 6,000 5,000 5 COAT ™ Continuous Open Airway Therapy
Slide 6: Strong growth in revenues and gross margin
SomnoMed: Global Strong growth in revenues and gross margin For personal use only Half Year Revenue and Margin Growth ( $000's ) 16000 16,000 14000 14,000 12000 12,000 Revenue Growth for half year CAGR Revenue = 38% 14/15 over 13/14 was 18% CAGR Gross Margin = 45% 10000 10,000 8000 8,000 Consistent
Slide 7: Regional highlights of the first half financial year 2014/15
SomnoMed: Regional Regional highlights of the first half financial year 2014/15 For personal use only • North America o Strong growth achieved in all three sales departments – dental, medical and managed care o Successful launch of SomnoDent Herbst Advance and SomnoDent® Fusion ( both September 2014
Slide 8: Summary Profit and Loss first half year
SomnoMed: Finance Summary Profit and Loss first half year For personal use only Financial Summary ( $000's ) 14/15 13/14 12/13 11/12 1st H 1st H 1st H 1st H Units 24,775 20,455 17,182 14,443 Revenue 14,819 12,553 9,026 6,846 Gross Margin 9,516 8,129 5,962 4,515 MAS Gross Margin % 68.5% 66.8% 68.3% 6
Slide 9: Expansion of global sales teams and infrastructure
SomnoMed: Finance Expansion of global sales teams and infrastructure For personal use only 9 COAT ™ Continuous Open Airway Therapy
Slide 10: SomnoMed maintains solid cash position
SomnoMed: Finance SomnoMed maintains solid cash position For personal use only Quarterly Group Cash Balance 10000000 10,000,000 9,000,000 9000000 8,000,000 8000000 7,000,000 7000000 Cash Balance A$ 6,000,000 6000000 5,000,000 5000000 4,000,000 4000000 3,000,000 3000000 2,000,000 2000000 1,000,000 10
Slide 11: Outlook second half 2014/2015
SomnoMed: Global Outlook second half 2014/2015 For personal use only GLOBAL • Unit sales to grow by 30.5% to 30,000 units, representing 55,000 units for full year • Revenues to grow by 35% to $18 million, representing $32.5 million for full year • EBITDA to exceed $1.6 million in second half, repres
Slide 12: Contact details
For personal use only Contact details EXECUTIVE CHAIRMAN & CEO Dr Peter Neustadt CHIEF FINANCIAL OFFICER Mr Neil Verdal–Austin Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (2) 9467 0400 Website www.somnomed.com.au COAT ™ Continuous Open Airway Therapy